Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The Bioavailability and Pharmacokinetics of Silymarin SMEDDS Formulation Study in Healthy Thai Volunteers.

Sornsuvit C, Hongwiset D, Yotsawimonwat S, Toonkum M, Thongsawat S, Taesotikul W.

Evid Based Complement Alternat Med. 2018 Jul 19;2018:1507834. doi: 10.1155/2018/1507834. eCollection 2018.

2.

NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.

Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, Royer HD, Communi D, Boeynaems JM, Hausmann R, Schmalzing G, Kassack MU.

J Pharmacol Exp Ther. 2010 Jan;332(1):238-47. doi: 10.1124/jpet.109.157750. Epub 2009 Oct 8.

PMID:
19815812
3.

Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).

Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M.

ChemMedChem. 2007 Oct;2(10):1419-31.

PMID:
17628866
4.

Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.

Ullmann H, Meis S, Hongwiset D, Marzian C, Wiese M, Nickel P, Communi D, Boeynaems JM, Wolf C, Hausmann R, Schmalzing G, Kassack MU.

J Med Chem. 2005 Nov 3;48(22):7040-8.

PMID:
16250663

Supplemental Content

Loading ...
Support Center